MedPath

To study the effect of anti-seizure drug named levetiracetam on body weight, blood pressure, blood cholesterol and blood sugar levels in adult patients having seizure disorder treated with levetiracetam.

Not Applicable
Completed
Conditions
Health Condition 1: G403- Generalized idiopathic epilepsy and epileptic syndromes
Registration Number
CTRI/2023/01/048946
Lead Sponsor
Pt BD Sharma PGIMS Rohtak
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
70
Inclusion Criteria

1) Patients of =18 to = 40 years of age of either gender.

2) Patients with newly diagnosed epilepsy.

3) Patients/LAR willing to provide written informed consent.

Exclusion Criteria

1) Patients with Body mass index (BMI) = 30 kg/m2.

2) Patients with co-existing Type 2 Diabetes mellitus and/or Hypertension.

3) Patients with dyslipidemia who are already on lipid-lowering agents.

4) Patients on medication that are known to interfere with body weight status, such as antidepressants, corticosteroids, and anti-thyroid drugs.

5) Pregnant patients of epilepsy.

6) Patients with a history of alcohol/ substance abuse.

7) Patients having any personality or psychiatric disorders.

8) Patients having severe physical disability, thyroid, liver, or renal dysfunction.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath